With focuses on developing high barrier drugs, specialty drugs and even new drugs, we had already expanded our footprint to beyond Taiwan market in as early as 2005, and had aggressively looked for collaboration partners in Europe, America and Asia. We have reached co-developments and licensing-out on several products focused on liposome technology and PLGA platform of which we have been engaged in cultivation for a long time. During the collaboration processes, our obviously differentiated products as well as almost seamless technology transfer have enabled our collaboration partners to obtain competitive advantages in target markets. In the meantime, we also understand that technology introduction conducted with collaboration partners of complimentary advantage plays an extremely critical role to new drug development. With our subsequent R&D strength, enhanced manufacturing process and marketing capability, we are also capable of allowing collaboration partners to obtain value maximization from technology introduction and achieve win-win status for both parties. Therefore, in addition to potential clients who are interested in our products and technologies, we also sincerely welcome partners possessing high potential molecular drugs to contact us.